Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)

NCT00536692 is registered in ClinicalTrials.gov with CoMentis as lead sponsor.

NCT NCT00536692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00536692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)
Lead sponsor
CoMentis
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
April 30, 2008
Enrollment
Not reported
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema